Lester and Sue Smith Breast Center at Baylor College of Medicine
Oncology
Dr. Mothaffar F. Rimawi, MD
|
|
Give Review
Mothaffar F. Rimawi, MD is an expert in the field of Oncology. He researched medicine at Baylor College of Medicine. He has 2 awards "Top Doctors:SE Texas" and "CMS Meaningful Use Stage 1 Certification". Mothaffar F. Rimawi, MD is a published doctor. He has 26 publications published. The most current publication "Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast C..." Mothaffar F. Rimawi, MD accepts Medicare.
Publications
- Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast C...
- A Phase II Trial of Capecitabine Concomitantly With Whole-Brain Radiotherapy Followed by Capecitabine and Sunitinib for Brain Metastases From Breast Cancer.
- Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast Cancer.
- Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
- Development of Acneiform Rash Does Not Predict Response to Lapatinib Treatment in Patients with Breast Cancer.
- A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast Cancer xenograft models.
- Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Recep...
- Predictors of post-mastectomy reconstruction in an underserved population.
- Jejunal intussusception due to malignant phyllodes tumor of the Breast.
- Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast Cancers - role of estrogen receptor and HER2 reactivation.
- ?1 integrin mediates an alternative survival pathway in breast Cancer cells resistant to lapatinib.
- High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti-IGF-IR Therapy.
- Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing Breast tumor xenografts.
- Epidermal growth factor receptor expression in breast Cancer association with biologic phenotype and clinical outcomes.
- Targeting HER2 for the treatment of breast Cancer.
- Self-blame, self-forgiveness, and spirituality in breast Cancer survivors in a public sector setting.
- Treatment of human epidermal growth factor receptor 2-overexpressing breast Cancer xenografts with multiagent HER-targeted therapy.
- Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-over...
- Advanced concepts in estrogen receptor biology and breast Cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
- DNA repair signature is associated with anthracycline response in triple negative breast Cancer patients.
- Tamoxifen resistance in Breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
- Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast Cancer.
- A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast Cancer.
- Making sense of clinical trial data: is inverse probability of censoring weighted Analysis the answer to crossover bias?
- Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked.
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Top Doctors:SE Texas
- CMS Meaningful Use Stage 1 Certification
Education
-
Baylor College of Medicine -
University of Jordan Faculty of Medicine
Hospital
-
Baylor St. Luke's Medical Center
Drug Facts
| NPI NUMBER | 1245241843 | |
| NPPES Provider LastName | RIMAWI | |
| NPPES Provider FirstName | MOTHAFFAR | |
| NPPES Provider ZIPCode | 770302348 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 449.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 30.0 | |
| Percent Opioid Claims | 6.68 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1245241843 |
| Last Name Of The Provider | RIMAWI |
| First Name Of The Provider | MOTHAFFAR |
| View All |
Similar Doctors
|
|
Dr. Vilmos A. Thomazy, MD |
|
|
Dr. Priya Ramshesh, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nizar M. Tannir, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Rachel L. Theriault, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John Thachil, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Fisch, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Sarvari V. Yellapragada, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leonard A. Zwelling, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Laura E. Sulak, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Muzaffar H. Qazilbash, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. George R. Blumenschein Jr., MD |